Skip to main content
. 2024 Jun 19;15(21):1665–1672. doi: 10.1111/1759-7714.15382

FIGURE 1.

FIGURE 1

Distribution of oncogenic driver alterations detected by the Amoy 9‐in‐1 assay (a) and the next‐generation sequencing (NGS) assays (b) in patients with non‐small cell lung cancer.